DCGI APPROVES PHASE II+III TRIALS OF OXFORD UNIVERSITY VACCINE

The Drugs Controller General of India (DCGI) has given approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India. This will hasten the development of the COVID-19 vaccine.

India continues to improve the Case Fatality Rate (CFR), and maintain its global position of having one of the lowest COVID fatalities rates. With a further fall, the current CFR touched 2.11% today. This is the outcome of the well conceived and effectively implemented strategy of “Test, Track and Treat” which has guided the COVID management in the country.